Recent Updates
Recently added Catalysts

GLPG3970

Phase 2

Rheumatoid Arthritis | Small molecule | Immunology |Galapagos NV|Last Updated: Jul 18, 2022

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment28
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04577781A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to MethotrexatePHASE2 COMPLETED 28Oct 12, 2020Apr 7, 2021Jul 18, 20229 Bulgaria, Georgia +2
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Change From Baseline in DAS-28 (CRP) at Week 6
Baseline and Week 6

The DAS28 (CRP) is a derived measurement with differential weighting given to each component such as TJC28, SJC28, patient's global assessment of disease activity, and serum CRP level. * TJC28 ranges from 0-28 * SJC28 ranges from 0-28 * High sensitivity C-reactive protein (hsCRP) (in mg/L) * Patient's disease activity VAS (in mm) (ranges from 0 = best to 100 = worst) The DAS28 (CRP) score was calculated using the below formula: DAS28 (CRP) = 0.56 x square root of TJC28 + 0.28 x square root of SJC28 + 0.36 x Ln\[1+CRP(in mg/L)\] + 0.014 x patient's disease activity VAS (in mm) + 0.96. A lower score is considered as better disease activity.

Secondary Endpoints
Number of Participants With Treatment Emergent Adverse Events
From first dose of study drug until end of the study (up to 8 weeks)
Plasma Concentration (Ctrough) of GLPG3970
Day 15: pre-dose; Day 29: pre-dose; Day 43: pre-dose
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
GLPG3970EXPERIMENTALParticipants received 400 milligrams (mg) GLPG3970 oral solution, once daily (QD) for a period of 6 weeks.
PlaceboPLACEBO_COMPARATORParticipants received GLPG3970 matching placebo oral solution, QD for a period of 6 weeks.
Interventions
NameTypeDescription
GLPG3970DRUGGLPG3970 powder and solvent for oral solution to be reconstituted prior to use.
PlaceboDRUGPlacebo powder and solvent for oral solution to be reconstituted prior to use.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 64 Years
SexALL
Healthy VolunteersNo
Study Sites9

Key Inclusion Criteria: 1. A body mass index (BMI) between 18-32 kg/m\^2, inclusive. 2. Diagnosis of RA ≥6 months prior to screening AND meeting the 2010 American College of Rheumatology (ACR)/ European League Against Rheumatism (EULAR) criteria of RA AND ACR functional class I-III. 3. Have ≥6 swol...

Countries:BulgariaGeorgiaPolandUkraine
Unlock Eligibility Criteria